Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2161402 | 0.83 | MAPT (0.67) | MAPTTP53POLBPPARGMEN1 | |
| SCHEMBL2004276 | 0.78 | PLA2G2A (0.60) | KDM4ELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2161521 | 0.76 | MAPT (0.55) | KDM4ECYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL1320560 | 0.76 | LMNA (1.00) | KDM4ELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7963796 | 0.73 | PLA2G2A (0.60) | KDM4ELMNAMAPTPKMPLA2G2A | |
| SCHEMBL2161474 | 0.73 | KDM4E (0.50) | KDM4ELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27734727 | 0.72 | PPARG (0.74) | MAPTTP53PPARGMEN1ALDH1A1 | |
| SCHEMBL8300412 | 0.72 | PLA2G2A (0.77) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6238935 | 0.71 | MMP13 (0.61) | KDM4ENPSR1TP53 | |
| SCHEMBL2007900 | 0.71 | PLA2G2A (0.63) | KDM4ELMNACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985764-B2 | Amide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988076-A1 | AMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | HTR7, HTR2B, NPSR1 | KDM4E 3397/4885LMNA 4394/4885CYP1A2 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.